The World Health Organization identified several experimental Ebola vaccines and treatments for evaluation within clinical trials on May 28, 2026 [1].
This move is critical because the current outbreak involves the Bundibugyo strain, which lacks a widely available approved vaccine and carries a high mortality rate. Testing these candidates allows health officials to determine which interventions are safe and effective for this specific strain while preparing for future emergencies [2, 3].
The outbreak is concentrated in the Democratic Republic of Congo [4]. Health officials have reported more than 130 deaths [5]. The Bundibugyo strain is particularly dangerous, with a fatality rate reaching up to 50% [6].
To address the crisis, the WHO prioritized three experimental treatments for testing [7]. These candidates will be administered only within the framework of clinical trials to ensure rigorous data collection. The organization said this approach is necessary to assess safety and effectiveness [2].
Rapid transmission has complicated the response. Reports indicate that the number of cases more than doubled in three days during a recent surge [8]. By utilizing clinical trials during the active outbreak, researchers can gather real-time data on how the vaccines perform against the virus in a field setting [3].
This strategy aims to bridge the gap between laboratory research and public health deployment. The WHO said the trials are intended to improve global preparedness for future Ebola outbreaks and ensure that the international community is not caught without tools when new strains emerge [2, 3].
“The Bundibugyo strain is particularly dangerous, with a fatality rate reaching up to 50%”
The decision to limit experimental vaccines to clinical trials reflects a balance between urgent need and patient safety. Because the Bundibugyo strain has a high fatality rate and is spreading rapidly, the WHO is using the current crisis as a live laboratory to accelerate the development of a permanent vaccine. This ensures that any future deployment is based on verified efficacy rather than desperation.
